Middletons lead biotechnology partner on the deal, Peter Howard said “Middletons has long acted for Mesoblast since the company’s inception and its initial public offering in 2004. It is always very satisfying to see our clients grow with us.”
Mr Howard said “Mesoblast has granted Cephalon exclusive rights to commercialise specified cardiac, central nervous disorder and oncology products based on the Mesoblast’s proprietary adult stem cell technology platform. The deal does not include the areas of orthopaedics, diabetes, eye diseases and immune based inflammatory diseases which are retained by Mesoblast. ”
Mr Howard said “This is a fantastic outcome for our client and a transformational deal for both parties. Under the deal, Cephalon will now partner with Mesoblast on clinical development and delivery and Mesoblast is free to use the technology in its other applications outside of this mutually beneficial relationship.”
Mr Gaffney said, “This deal was truly unique with no bankers or financiers involved on the transaction for Mesoblast. Middletons acted in concert with US law firm Wilson Sonsini Goodrich & Rosati.”
Mr Howard said, “We have specialised qualifications which, when coupled with industry experience in the biotechnology sector, is extremely valuable to businesses like Mesoblast. We have intimate knowledge of the process required to take technologies from concept to product to market and the key players and steps required along the way.”
Related Posts:
- None Found